Envista Holdings Co. (NYSE:NVST) Position Lessened by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. decreased its position in shares of Envista Holdings Co. (NYSE:NVST) by 80.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 33,369 shares of the company’s stock after selling 136,496 shares during the period. Landscape Capital Management L.L.C.’s holdings in Envista were worth $644,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Amalgamated Bank lifted its holdings in shares of Envista by 0.7% during the 4th quarter. Amalgamated Bank now owns 80,380 shares of the company’s stock valued at $1,551,000 after buying an additional 523 shares during the last quarter. GAMMA Investing LLC raised its position in Envista by 30.5% during the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock valued at $44,000 after acquiring an additional 538 shares in the last quarter. M&T Bank Corp lifted its stake in Envista by 4.2% in the fourth quarter. M&T Bank Corp now owns 16,621 shares of the company’s stock valued at $320,000 after acquiring an additional 676 shares during the last quarter. Assetmark Inc. grew its position in Envista by 2.5% in the fourth quarter. Assetmark Inc. now owns 39,624 shares of the company’s stock worth $764,000 after acquiring an additional 983 shares in the last quarter. Finally, Xponance Inc. increased its stake in shares of Envista by 5.8% during the 4th quarter. Xponance Inc. now owns 19,726 shares of the company’s stock worth $381,000 after purchasing an additional 1,077 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on NVST shares. New Street Research set a $19.00 price objective on shares of Envista in a research note on Thursday, March 6th. Morgan Stanley decreased their price target on Envista from $20.00 to $19.00 and set an “equal weight” rating for the company in a research note on Thursday, March 6th. JPMorgan Chase & Co. cut their price objective on Envista from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Envista in a research report on Thursday, March 6th. Finally, Jefferies Financial Group lifted their price target on shares of Envista from $20.00 to $22.00 and gave the company a “hold” rating in a research report on Thursday, January 23rd. Two analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $20.18.

Envista Stock Performance

NYSE:NVST opened at $15.47 on Monday. The firm’s 50-day moving average is $19.18 and its 200-day moving average is $19.53. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. Envista Holdings Co. has a 52-week low of $14.77 and a 52-week high of $23.00. The company has a market cap of $2.66 billion, a price-to-earnings ratio of -2.38, a PEG ratio of 1.27 and a beta of 1.12.

Envista (NYSE:NVST) last issued its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Equities research analysts anticipate that Envista Holdings Co. will post 1 earnings per share for the current year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.